PMC

A, B, Treatment history of Pt-12, Pt-65 and flow analysis of their diagnosis (Dx) and relapse (Rl) specimens. In the CD45/SSC plots, Mono, Prim and Lym gates identify monocytic, primitive and lymphocytic populations, respectively. The CD34/CD117 and CD68/CD11b plots show immunophenotype of the gated primitive subpopulations in blue and monocytic subpopulations in red. Arrows highlight populations of interest. Clinical information of these patients is listed in .
C, D, Fish plots showing clonal dynamics in paired diagnosis (Dx) and relapse (Rl) specimens of Pt-12 and Pt-65. Genetic subclones are illustrated by distinct shapes accompanied by their clonal number (1, 2, or 3). Phenotypic subpopulations are illustrated by color as follows: teal indicates primitive phenotype; brown, pink or red indicate monocytic phenotype. For Pt-12, clone 1 presents a primitive phenotype; clone 2 presents a monocytic phenotype. For Pt-65, clone 1 presents a mixed monocytic and primitive phenotype; clone 2 presents a monocytic phenotype; clone 3 is inferred to have a monocytic phenotype as well.

A Less circulatory and hepatic monocytic MDSCs in CXCL10^−/− mice compared to wild-type ones. B Significantly decreased mobilization and recruitment of monocytic MDSCs in TLR4^−/− mice. C No significant change of circulatory and hepatic monocytic MDSCs by knockout of CXCR3. D Reduced TLR4⁺ monocytic MDSCs in the circulation and liver of CXCL10^−/− mice compared to wild-type ones after IRH. N = 5/group; Error bars indicate Standard Error of Mean; *p < 0.05, **p < 0.01. MDSC myeloid-derived suppressor cell, IRH ischemia/reperfusion plus major hepatectomy, WT wild type.

In vitro vasculogenic property of monocytic EPCs in Matrigel^® culture. Monocytic EPCs labeled with PKH67 (green) and HUVECs labeled with Dil-acetylated LDL (red) were cultured together on Matrigel^®. (a) Typical phase-contrast (left) and fluorescent (right) images of the same field of monocytic EPCs from an SSc patient (upper) and a healthy control (lower). An arrow indicates a monocytic EPC-derived cell incorporated into the tubular structure. Scale bars = 100 μm. (b) The vasculogenic property of monocytic EPCs was calculated as the number of monocytic EPCs within the tubular structure divided by the total tube length (cells/mm), and compared between SSc patients and healthy controls. Horizontal bars indicate the mean values.

Flow cytometric analysis of monocytic CD11b and CX3CR1 expression in classical monocytes (CM), intermediate monocytes (IM), and non-classical monocytes (NCM) in PBMC from healthy donors and HNSCC patients. (A) Active-smoking HNSCC patients revealed significantly increased expression levels of monocytic CD11b compared to healthy donors. (B) HNSCC patients revealed significantly decreased expression levels of monocytic CX3CR1 in classical monocytes and intermediate monocytes from active-smoking patients compared to healthy donors. (C) HNSCC patients revealed significantly increased expression levels of monocytic CD11b compared to healthy donors. (D) HNSCC patients revealed significantly decreased expression levels of monocytic CX3CR1 in classical monocytes and intermediate monocytes compared to healthy donors. (E) HNSCC patients ≤ 65 revealed significantly increased expression levels of monocytic CD11b compared to healthy donors and HNSCC patients ˃ 65. (F) HNSCC patients ≤ 65 revealed significantly decreased expression levels of monocytic CX3CR1 compared to healthy donors and HNSCC patients ˃ 65. * p < 0.05; ** p < 0.01.